144 related articles for article (PubMed ID: 30362665)
1. Strategies for targeting energy metabolism in Kirsten rat sarcoma viral oncogene homolog -mutant colorectal cancer.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Biochem; 2019 Feb; 120(2):1106-1121. PubMed ID: 30362665
[TBL] [Abstract][Full Text] [Related]
2. Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy.
Wang G; Wang JJ; Yin PH; Xu K; Wang YZ; Shi F; Gao J; Fu XL
J Cell Physiol; 2019 May; 234(5):5601-5612. PubMed ID: 30341899
[TBL] [Abstract][Full Text] [Related]
3. Relationship Between 18F-Fluorodeoxyglucose Uptake and V-Ki-Ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Mutation in Colorectal Cancer Patients: Variability Depending on C-Reactive Protein Level.
Lee JH; Kang J; Baik SH; Lee KY; Lim BJ; Jeon TJ; Ryu YH; Sohn SK
Medicine (Baltimore); 2016 Jan; 95(1):e2236. PubMed ID: 26735530
[TBL] [Abstract][Full Text] [Related]
4. The response of PIK3CA/KRAS-mutant colorectal cancer stem-like cells to RGD-peptide FraC produced by the strawberry anemone: A promising water-soluble peptide-based inhibitor of metastasis-driver gene CXCR4, stem cell regulatory genes and self-renewal.
Sarkhosh-Inanlou R; Imani M; Sam MR
Biomed Pharmacother; 2020 Dec; 132():110807. PubMed ID: 33068939
[TBL] [Abstract][Full Text] [Related]
5. Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2020 Apr; 16(4):51. PubMed ID: 32300895
[TBL] [Abstract][Full Text] [Related]
6. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK
J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618
[TBL] [Abstract][Full Text] [Related]
7. The current understanding on the impact of KRAS on colorectal cancer.
Meng M; Zhong K; Jiang T; Liu Z; Kwan HY; Su T
Biomed Pharmacother; 2021 Aug; 140():111717. PubMed ID: 34044280
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA‑337 inhibits colorectal cancer progression by directly targeting KRAS and suppressing the AKT and ERK pathways.
Liu X; Wang Y; Zhao J
Oncol Rep; 2017 Nov; 38(5):3187-3196. PubMed ID: 29048669
[TBL] [Abstract][Full Text] [Related]
9. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with
Ohishi T; Kato Y; Kaneko MK; Ohba SI; Inoue H; Harakawa A; Kawada M
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32839411
[TBL] [Abstract][Full Text] [Related]
10. Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/V-raf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer.
Yokota T; Shibata N; Ura T; Takahari D; Shitara K; Muro K; Yatabe Y
Transl Res; 2010 Aug; 156(2):98-105. PubMed ID: 20627194
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
12. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
13. Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.
Bteich F; Mohammadi M; Li T; Bhat MA; Sofianidi A; Wei N; Kuang C
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569406
[TBL] [Abstract][Full Text] [Related]
14. Multifunctional imaging signature for V-KI-RAS2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in colorectal cancer.
Miles KA; Ganeshan B; Rodriguez-Justo M; Goh VJ; Ziauddin Z; Engledow A; Meagher M; Endozo R; Taylor SA; Halligan S; Ell PJ; Groves AM
J Nucl Med; 2014 Mar; 55(3):386-91. PubMed ID: 24516257
[TBL] [Abstract][Full Text] [Related]
15. Modulating Pluripotency Network Genes with Omega-3 DHA is followed by Caspase- 3 Activation and Apoptosis in DNA Mismatch Repair-Deficient/KRAS-Mutant Colorectal Cancer Stem-Like Cells.
Mahmoudi N; Delirezh N; Sam MR
Anticancer Agents Med Chem; 2020; 20(10):1221-1232. PubMed ID: 32116204
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Identification of Sulfasalazine's Therapeutic Potential for Suppressing Colorectal Cancer Stemness and Metastasis through Targeting KRAS/MMP7/CD44 Signaling.
Leung WH; Shih JW; Chen JS; Mokgautsi N; Wei PL; Huang YJ
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203586
[TBL] [Abstract][Full Text] [Related]
17.
Li ZN; Zhao L; Yu LF; Wei MJ
Gastroenterol Rep (Oxf); 2020 Jun; 8(3):192-205. PubMed ID: 32665851
[TBL] [Abstract][Full Text] [Related]
18. Integration of signaling pathway and bromodomain and extra-terminal domain inhibition for the treatment of mutant Kirsten rat sarcoma viral oncogene homolog cancer.
Hamilton G; Stickler S; Rath B
Explor Target Antitumor Ther; 2023; 4(5):1027-1038. PubMed ID: 38023987
[TBL] [Abstract][Full Text] [Related]
19. Activated cMET and IGF1R-driven PI3K signaling predicts poor survival in colorectal cancers independent of KRAS mutational status.
Lee J; Jain A; Kim P; Lee T; Kuller A; Princen F; In-GuDo ; Kim SH; Park JO; Park YS; Singh S; Kim HC
PLoS One; 2014; 9(8):e103551. PubMed ID: 25090459
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA SNHG14 accelerates cell proliferation, migration, invasion and suppresses apoptosis in colorectal cancer cells by targeting miR-944/KRAS axis through PI3K/AKT pathway.
Pei Q; Liu GS; Li HP; Zhang Y; Xu XC; Gao H; Zhang W; Li T
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9871-9881. PubMed ID: 31799655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
